Loading stock data…
$26.87-1.36 (-4.82%)
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.
ZBIO in the Healthcare sector is trading at $26.87 with a market capitalization of $2.1B. Wall Street consensus targets $47.88 (8 analysts), implying a +78.2% move over the next 12 months. The stock is currently 40% below its 52-week high of $44.60, remaining 8.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.00M | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$77.66M↓ | -$77.35M↓ | -$71.31M↓ | -$47.58M↑ | -$55.16M |
| Net Income | -$111.46M↓ | -$80.99M↑ | -$240.44M↓ | -$51.50M↑ | -$52.22M |
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD...